Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Special Meeting Materials
    • Annual Meeting Materials
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • FBIOP Announcements
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Fortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016

Mar 16, 2017

Fortress Biotech Forms New Subsidiary, Cyprium Therapeutics, Inc., to Develop Novel Therapies for Menkes Disease and Related Copper Metabolism Disorders

Mar 14, 2017

Checkpoint Therapeutics to Present at the 29th Annual ROTH Conference

Mar 09, 2017

Fortress Biotech to Present at the 29th Annual ROTH Conference

Mar 09, 2017

Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lung Cancer Compound CK-101

Feb 28, 2017

Fortress Biotech Announces that its Subsidiary, Mustang Bio, Closes $94.5 Million Private Placement Financing

Feb 02, 2017

Fortress Biotech Forms New Subsidiary, Caelum Biosciences, Inc., to Develop Novel Treatment for AL Amyloidosis

Jan 04, 2017

Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol

Jan 03, 2017

Fortress Biotech Announces Publication on MB‐101 (IL13Rα2‐specific CAR T cells) for the Treatment of Glioblastoma in New England Journal of Medicine

Dec 28, 2016

Clinical and Pre-Clinical Data on Mustang Bio’s MB-101 (IL13Rα2-specific CAR T cells) for the Treatment of Glioblastoma (GBM) Presented at the 21st Annual Meeting and Education Day of the Society for Neuro-Oncology

Nov 21, 2016
RSS
  • Prev
    • 1...
    • 48
    • 49
    • 50
    • 51
    • 52
    • 53
    • 54
    • 55
    • 56
    • 57
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2023 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap